News | March 05, 2012

SciFluor Extends License With Harvard to Advance Use of PET Imaging

March 5, 2012 — SciFluor Life Sciences announced an agreement with Harvard University that extends its license of proprietary fluorine technology to the rapidly growing field of positron emission tomography (PET) imaging. Under the new agreement, SciFluor gains access to technology that enables the rapid, efficient synthesis of 18F-labeled molecules, which empower PET imaging for a new level of informed and predictive drug development. The company previously announced an exclusive, worldwide license from Harvard University to various fluorination methods and to a portfolio of novel fluorinated compounds.

“We are pleased to further expand the breadth of our innovative fluorine technologies and to extend our licensing agreement with Harvard,” said Arthur Hiller, CEO of SciFluor Life Sciences. “With this new technology, SciFluor is now capable of developing sophisticated 18F PET tracers that were previously inaccessible. This advance paves the way to significantly expand the capabilities of PET imaging in the drug discovery and development process by providing researchers with new insights into a drug candidate’s potential efficacy, safety and optimal dosing. Our initial focus will be on identifying industry partnerships between SciFluor and companies with drug pipelines and research priorities that benefit from applying this fluorination technology, which ultimately could result in shorter development times, improved clinical trial designs and more revolutionary therapies for patients.”

By utilizing SciFluor technology in PET imaging, researchers will now be able to observe a broader range of a drug’s cellular and metabolic activity in vivo to determine, for example, the drug’s capacity to cross the blood-brain barrier, its ability to hit the relevant biological targets, and the drug’s dose effectiveness and potential clinical benefit.

This newly licensed technology was recently described in the paper, “A Fluoride-Derived Electrophilic Late-Stage Fluorination Reagent for PET Imaging,” published in the Nov. 4, 2011, issue of Science and co-authored by Tobias Ritter, Ph.D., founder and chief technology officer of SciFluor.

For more information: www.scifluor.com

Related Content

United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...